Abstract
Cancer stem cell-like cells (CSCs) are cancer cells that have the ability of self-renewal and differentiation into multiple malignant cell types (hierarchy). Thus, can cause relapses and metastasis. CSCs’ phenotype is defined by special transcription factors such as Nanog, Oct3/4, Sox2, Nestin, and CD34. The present study aims to determine the change in gene expression of the above markers in correlation with the stage of the disease in breast cancer patients. Initially, whole blood samples from patients with breast cancer were collected, followed by the isolation and culture of circulating tumor cells (CTCs). This was followed by the quantification of CSCs from the above cultures. CSCs’ molecular analysis was performed with qPCR, with the use of gene specific primers. At the same time of the analysis, the clinical assessments of the patients were requested from their physicians. The results indicated a linear relationship between the gene expression of stemness markers and the stage of the disease, as well as specific expression patterns by stage. It seems that these genes have an important role in the progression of the disease, thus they might be target for new treatment approaches.
Keywords: Breast cancer, cancer stem cells, nanog, Sox2, Oct3/4, CD34, nestin, cancer cells, peripheral blood mononuclear cells
Current Stem Cell Research & Therapy
Title:Cancer Stem Cells Stemness Transcription Factors Expression Correlates with Breast Cancer Disease Stage
Volume: 7 Issue: 6
Author(s): Panagiotis Apostolou, Maria Toloudi, Marina Chatziioannou, Eleni Ioannou and Ioannis Papasotiriou
Affiliation:
Keywords: Breast cancer, cancer stem cells, nanog, Sox2, Oct3/4, CD34, nestin, cancer cells, peripheral blood mononuclear cells
Abstract: Cancer stem cell-like cells (CSCs) are cancer cells that have the ability of self-renewal and differentiation into multiple malignant cell types (hierarchy). Thus, can cause relapses and metastasis. CSCs’ phenotype is defined by special transcription factors such as Nanog, Oct3/4, Sox2, Nestin, and CD34. The present study aims to determine the change in gene expression of the above markers in correlation with the stage of the disease in breast cancer patients. Initially, whole blood samples from patients with breast cancer were collected, followed by the isolation and culture of circulating tumor cells (CTCs). This was followed by the quantification of CSCs from the above cultures. CSCs’ molecular analysis was performed with qPCR, with the use of gene specific primers. At the same time of the analysis, the clinical assessments of the patients were requested from their physicians. The results indicated a linear relationship between the gene expression of stemness markers and the stage of the disease, as well as specific expression patterns by stage. It seems that these genes have an important role in the progression of the disease, thus they might be target for new treatment approaches.
Export Options
About this article
Cite this article as:
Apostolou Panagiotis, Toloudi Maria, Chatziioannou Marina, Ioannou Eleni and Papasotiriou Ioannis, Cancer Stem Cells Stemness Transcription Factors Expression Correlates with Breast Cancer Disease Stage, Current Stem Cell Research & Therapy 2012; 7 (6) . https://dx.doi.org/10.2174/157488812804484639
DOI https://dx.doi.org/10.2174/157488812804484639 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy
Current Pharmaceutical Design Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required
Current Cancer Drug Targets New Antimicrobial Frontiers
Mini-Reviews in Medicinal Chemistry Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets Clinical Application of Ghrelin
Current Pharmaceutical Design Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Novel Molecular-Targeted Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Radiobromine-Labelled Tracers for Positron Emission Tomography: Possibilities and Pitfalls
Current Radiopharmaceuticals Recent Advances in Pharmacological Interventions of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome
Current Pharmaceutical Design Recent Patents on Anti-Cancer Potential of Helenalin
Recent Patents on Anti-Cancer Drug Discovery Understanding the Structural Basis for Inhibition of Cyclin-Dependent Kinases. New Pieces in the Molecular Puzzle
Current Drug Targets Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy
Current Medicinal Chemistry Weka Machine Learning for Predicting the Phospholipidosis Inducing Potential
Current Topics in Medicinal Chemistry Nuclear Receptor SHP as a Potential Therapeutic Target for Liver Cancer
Current Cancer Therapy Reviews Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles
Current Pharmaceutical Design An Integrative Systems Analysis of High-grade Glioma Cell Lines: TLRs, Wnt, BRCA1, Netrins, STXBP1 and MDH1 Provide Putative Molecular Targets for Therapeutic Intervention
Current Pharmacogenomics and Personalized Medicine Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry Interleukin 10 in Antiviral Responses
Current Immunology Reviews (Discontinued)